Patients with and without diabetes respond similarly to extended dosing of epoetin alfa as infrequently as once every four weeks, data show.
Robert Provenzano, MD, of St. John Hospital and Medical Center in Detroit, and Ajay K. Singh, MD, of Brigham and Women’s Hospital in Boston, conducted a post hoc analysis of data from the PROMPT study. Subjects had CKD but were not on dialysis. They also had stable hemoglobin (Hb) levels of 11 g/dL or higher and had been receiving epoetin alfa for two or more months.
Patients received one of four dosing regimens for up to 16 weeks: 10,000 U once weekly (QW); 20,000 U every two weeks (Q2W); 30,000 U every three weeks (Q3W); and 40,000 U every four weeks (Q4W). The primary end point was the percent of patients achieving Hb maintenance, defined as a mean Hb level of 11 g/dL or more from week 2 to the final measurement.
Among the 445 subjects, 201 had diabetes and 244 did not. Mean baseline Hb was 11.9 g/dL in both groups. The percentage of patients achieving Hb maintenance, stratified by epoetin alfa dosing regimen, was similar in diabetics and non-diabetics, the authors reported in Endocrine Practice (2007;13:251-259).
The percentages were 90.2% and 96.5%, respectively, for those receiving the drug QW; 91.1% and 87.9% for those receiving Q2W dosing; 80% and 75.7% for subjects assigned to Q3W dosing; and 79.2% and 72.5% for patients receiving Q4W dosing. Both groups had a similar low incidence of adverse effects.